Patrick Hilden, MS

Research Biostatistician
Office Phone:
646-888-8131
Office Fax:
646-735-0010
Education:
University of Minnesota

Current Research Interests:

Since beginning at Memorial Sloan Kettering, Mr. Hilden has primarily collaborated with Dr. Devlin and the Bone Marrow Transplantation Service on a variety of projects, including the analysis of retrospective studies and the design of phase I and II clinical trials. Their works has evaluated post-transplant biomarkers to predict transplant-related mortality and graft-versus-host disease, and compared clinical outcomes between T-cell depleted and unmodified transplantation techniques. Mr. Hilden also collaborates with members of the Pediatric Long-Term Follow-Up Program to determine late effects related to the treatment of childhood cancers, as well as the Lymphoma Service in analyzing high-throughput screening data to evaluate the synergistic effect of drug combinations.

Publications by Patrick Hilden
  1. Brennan C, Yang TJ, Hilden P, Zhang Z, Chan K, Yamada Y, Chan TA, Lymberis SC, Narayana A, Tabar V, Gutin PH, Ballangrud Å, Lis E, Beal K. A Phase 2 Trial of Stereotactic Radiosurgery Boost After Surgical Resection for Brain Metastases.  Int J Radiat Oncol Biol Phys. 2014. 88(1): p. 130-136.
  2. Lendvai N, Hilden P, Devlin S, Landau H, Hassoun H, Lesokhin AM, Tsakos I, Redling K, Koehne G, Chung DJ, Schaffer WL, Giralt SA. A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 2014. 124(6): p. 899-906.
  3. Casey DL, Friedman DN, Moskowitz CS, Hilden PD, Sklar CA, Wexler LH, Wolden SL. Second Cancer Risk in Childhood Cancer Survivors Treated With Intensity-Modulated Radiation Therapy (IMRT). Pediatr Blood Cancer. 2015. 62(2): p.311-316.
  4. Ponce DM, Hilden P, Mumaw C, Devlin SM, Lubin M, Giralt S, Goldberg JD, Hanash A, Hsu K, Jeng R, Perales MA, Sauter C, van den Brink MR, Young JW, Brentjens R, Kernan NA, Prockop S, O’Reilly RJ, Scaradavou A, Paczesny S, Barker JN. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood. 2015. 125(1): p. 199-205.